3billion, a company that uses artificial intelligence to diagnose rare genetic diseases, said on March 31, 2026, that it has launched the Family Insight Test, a precision genomic diagnostic test for families. Family Insight makes use of WES and WGS analysis to test genetic roots of unexplained infertility with whole exome sequencing - WES and whole genome sequencing - WGS analysis in order to help people and families who have had problems during pregnancy and childbirth or who have a family history of genetic disorders.

3billion has mostly been looking for genetic causes in rare disease patients who have symptoms that lack a clear cause. The company's proprietary AI-based genetic variant interpretation technology is now available to families through the new service. This lets users check ahead of time if a disease is likely to happen.

Taking into account the genetic roots of unexplained infertility, the Family Insight Test is aimed at high-risk groups, such as couples who can't get pregnant for no apparent reason or who have had multiple miscarriages, cases where getting patient samples is hard and family-based alternative diagnosis is needed, and people with a family history of genetic diseases who want to know their own risk ahead of time.

The service also offers Carriership Finding, which looks at differences in autosomal recessive and X-linked disorders across about 2,000 important genes. This looks at the risk of passing on genetic diseases to children even when parents don't show any signs, thereby supporting family planning based on data.

With this launch, 3billion wants to reach more customers than just the genetics specialist-centred market. They want to reach large obstetrics and gynaecology hospitals, in vitro fertilization - IVF clinics, and family planning counselling centres.

Before the service went live, the company ran pilot tests in parts of the Middle East and Africa where a lot of people marry their cousins. This indicated that there was a need for genetic risk management and that the market was viable. The company plans to offer the service in areas with high birth rates, such as Asia and South America, based on these results. Keum Chang-won, CEO of 3billion, said, "We have extended the AI genetic variant interpretation technology accumulated through rare disease diagnosis beyond individuals to the family unit. "Our goal is to reduce genetic uncertainty and support safer family planning."

3billion plans to grow beyond rare disease diagnosis into precision medicine that helps individuals and families make decisions about their genetic risk. This will go on to strengthen its position as an AI genomic data platform company.